Smith & Nephew : Strategically right, but progress will not be visible in the short term
>2022 will be transitional – no visibility before Q3 - While Smith & Nephew guides for underlying revenue growth of 4-5% in FY 2022, the phasing will be back-end loaded in our view. Coronavirus-related headwinds will affect the first quarter and supply challenges should be a burden in the first half. Correspondingly, the underlying momentum in Orthopaedics and ENT are predicted to improve over the course of the year on the back of a recovery in the related markets as ...Smith & Nephew is a global medical devices business operating in the markets for advanced surgical devices comprising orthopaedic reconstruction and trauma, sports medicine and advanced wound management. Co.'s advanced medical products and services include: Orthopaedic Reconstruction and Trauma (joint replacement systems for knees and hips and products to help repair broken bones); Advanced Wound Management (treatment and prevention products for hard-to-heal wounds); and Sports Medicine (implants and enabling technologies for minimally invasive repair of the joint).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.